Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate and NTI for Cancer Fatigue
NCT00424099Phase 3Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2007
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of methylphenidate hydrochloride extended-release chewable tablet in cancer-related fatigue (CRF), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2007; status: completed.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
cancer-related fatigue (CRF)
Beyond the preview
Go deeper on NCT00424099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00424099.